Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | EPAS1 | Q99814 | 9/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4102645 | 0.79 | KDM4E (0.50) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL329419 | 0.71 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL11594753 | 0.71 | MAPT (0.46) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL7447286 | 0.71 | EPAS1 (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL28563540 | 0.70 | MAPT (0.60) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL30987223 | 0.70 | MAPT (0.60) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL329569 | 0.67 | MAPT (0.61) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL290849 | 0.67 | KDM4E (1.00) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL446289 | 0.67 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 | |
| SCHEMBL12329 | 0.67 | MAPT (0.56) | MAPTKDM4EALDH1A1HSD17B10EPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6908926-B1 | Substituted imidazoles, their preparation and use | NOVO NORDISK A/S (DK) | 2005-06-21 | — | — | US | claimed |
| US-10683274-B2 | 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof | BOSTON BIOMEDICAL, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190241535-A1 | 3-SUBSTITUTED CARBONYL-NAPHTHO[2,3-B]FURANE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | BOSTON BIOMEDICAL, INC. | 2019-08-08 | — | — | US | disclosed |
| US-10017488-B2 | 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof | BOSTON BIOMEDICAL, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9777000-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20170174646-A1 | 3-SUBSTITUTED CARBONYL-NAPHTHO[2,3-B]FURANE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | BOSTON BIOMEDICAL, INC. (US) | 2017-06-22 | — | — | US | disclosed |
| EP-2842944-B1 | METHOD FOR PRODUCING NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | NIPPON SODA CO (JP) | 2017-03-15 | — | — | EP | disclosed |
| EP-3102036-A1 | 3-SUBSTITUTED CARBONYL-NAPHTHO[2,3-B]FURANE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Boston Biomedical, Inc. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160347751-A1 | NOVEL PYRAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-12-01 | — | — | US | disclosed |
| US-9458157-B2 | Pyrazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2016-10-04 | — | — | US | disclosed |
| EP-2518064-A1 | NOVEL ARYL UREA DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2518060-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
| EP-2415764-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | Kowa Company, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | KOWA COMPANY, LTD. (JP) | 2012-01-05 | — | — | US | disclosed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20100222347-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA, COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | KOWA COMPANY, LTD. (JP) | 2010-09-02 | — | — | US | disclosed |
| EP-2199283-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA, COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | Kowa Company, Ltd. (JP) | 2010-06-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241535-A1 | 3-SUBSTITUTED CARBONYL-NAPHTHO[2,3-B]FURANE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | FGFR3, FGFR1, FGF2 | MAPT 4448/4885KDM4E 1227/4885ALDH1A1 254/4885 |
| US-20170174646-A1 | 3-SUBSTITUTED CARBONYL-NAPHTHO[2,3-B]FURANE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | FGFR3, FGFR1, FGF2 | MAPT 4448/4885KDM4E 1227/4885ALDH1A1 254/4885 |
| US-20120004197-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | EPOR, HBG1, HBG2 | MAPT 4876/4885KDM4E 1814/4885ALDH1A1 1491/4885 |
| US-20160347751-A1 | NOVEL PYRAZOLE DERIVATIVE | PDE10A, PDE3A, PDE5A | MAPT 75/4885KDM4E 1309/4885ALDH1A1 387/4885 |
| US-20100222347-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR ANEMIA, COMPRISING TETRAHYDROQUINOLINE COMPOUND AS ACTIVE INGREDIENT | EPOR, HBG2, HBG1 | MAPT 4884/4885KDM4E 1283/4885ALDH1A1 1956/4885 |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | MAPT 4385/4885KDM4E 2641/4885ALDH1A1 2875/4885 |
| US-10683274-B2 | 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof | FGFR3, FGFR1, FGF2 | MAPT 4448/4885KDM4E 1227/4885ALDH1A1 254/4885 |
| US-10017488-B2 | 3-substituted carbonyl-naphtho[2,3-B]furane derivative or pharmaceutically acceptable salt thereof | FGFR3, FGFR1, FGF2 | MAPT 4448/4885KDM4E 1227/4885ALDH1A1 254/4885 |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | JAK3, JAK1, UACA | MAPT 1412/4885KDM4E 1516/4885ALDH1A1 2676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.